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David Price1, Brooke Harrow2, Mark Small3, James Pike3 and Victoria Higgins3*Background: Inhaled asthma medications are the mainstay of treatment for chronic asthma. However, nonadherence
rates for long-term inhaler therapy among adults are estimated to exceed 50 %. Nonadherence is associated with
unfavorable clinical outcomes and diminished quality of life. Research suggests that adherence is associated with
patients’ satisfaction with their treatment regimen and other factors, such as concomitant allergic rhinitis and
tobacco use.
Methods: This prospective, cross-sectional survey of physicians and their patients evaluated the relationship
between patient satisfaction with attributes of inhaler devices, treatment adherence, and clinical outcomes. Primary
care and specialist physicians completed a physician-reported patient record form for patients with a confirmed
asthma diagnosis. Patients for whom a physician-reported form was completed were invited to complete a
patient-reported form. Both surveys collected information about demographics, symptoms, exacerbation history,
treatment, smoking status, comorbidities, type of inhaler device, and treatment adherence. Patients also indicated
the degree to which they were satisfied with attributes of their currently prescribed inhaler device(s). Partial least
squares path modeling quantified relationships between latent variables and clinical outcomes.
Results: A total of 243 patients were included in our analysis and 41 % had poorly controlled asthma. More favorable
clinical outcomes were significantly associated with greater patient satisfaction with drug delivery (P = 0.002), higher
medication adherence (P = 0.049), no history of tobacco use (P < 0.001), and absence of comorbid allergic rhinitis
(P = 0.005). Attributes associated with device satisfaction included patient perceptions of consistency in the
amount of drug delivery to the lungs, ease of use, and feedback about the number of remaining doses.
Conclusions: Higher patient satisfaction with their asthma drug delivery inhaler device is a significant predictor
of more favorable clinical outcomes while allergic rhinitis and smoking history were negatively associated with
optimal control of asthma. These findings provide clinicians with opportunities to improve patients’ clinical
outcomes by tailoring choice of inhaler device therapy and providing education about the correct way to use
the device to ensure optimal outcomes. Patients will likely benefit from medical therapy to manage comorbid
allergic rhinitis and smoking cessation interventions. Patients unable to stop smoking may require alternative
medical therapies to improve their clinical outcomes.
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Inhaler therapy is the cornerstone of treatment for
asthma, with pressurized metered dose inhalers and dry
powder inhalers the most frequently used inhalation
devices [1, 2], with numerous drug-inhaler combinations
currently available to prescribers and patients [3]. Des-
pite the efficacy of inhaled asthma medications, it is esti-
mated that 50 % of adults and children on long-term
therapy for asthma fail to adhere to their treatment regi-
men [4], with one study reporting that 84.6 % of patients
demonstrated some degree of nonadherence [5]. Among
older adults with asthma, 57 % demonstrated poor medi-
cation adherence [6].
Nonadherence is considered a key predictor for the
failure of patients to attain and maintain their treatment
goals, which results in poor health and quality of life
outcomes in asthma [7] as well as other chronic diseases
[8]. While adherence plays a critical role in achieving op-
timal outcomes for patients with asthma, other factors
that may affect symptom control also merit consider-
ation. Specifically, poor asthma control is associated with
concomitant allergic rhinitis (AR) [9–14], and less favor-
able outcomes are reported for patients who have
concomitant AR [15–18]. Current use of tobacco also
compromises the outcomes of patients with asthma,
[10, 19–23] with evidence to suggest that active smoking
is associated with symptom exacerbation, more rapid
declines in lung function [20, 24, 25], and a reduced re-
sponse to inhaled corticosteroids (ICS) [25–28]. These
findings have led to the recognition that patients with
asthma who also use tobacco products may require
treatment regimens that target inflammation of the
small airways [21].
Research suggests that treatment adherence among
patients with chronic health conditions, including
asthma, is predicted, in part, by patients’ satisfaction
with their treatment regimen [6, 29–32]. Several studies
report a positive relationship between adherence to
asthma medications and treatment satisfaction [6, 31, 33],
as well as in other chronic diseases [32]. Satisfaction
with asthma management was 1 of 7 themes identified
in a factor analysis of items that were significantly asso-
ciated with adherence [33]. A cross-sectional study
assessed physicians’ perceptions of patient adherence
with administration frequency and inhaler device usage
and patient satisfaction ratings for 13 attributes of their
inhaler device. Notably, higher adherence ratings were
associated with greater patient-reported satisfaction
with their device [31].
This research was undertaken to identify the relation-
ship among satisfaction with attributes of inhaler de-
vices, treatment adherence, and clinical outcomes in
adult patients with asthma. In particular, we sought to
expand on earlier research [31] by examining relationshipsamong patient satisfaction with specific attributes of in-
haler devices and treatment adherence on measures of
asthma control and overall health status. We also evaluated
the impact of comorbid AR and tobacco use on the same
clinical outcomes in this patient population, 2 factors also
deemed to be modifiable through appropriate treatment
adjustment or change in exposure.
Methods
Study design
This was a prospective, cross-sectional survey of physi-
cians and their patients, with data collected through the
US 2013 Adelphi Disease Specific Program (DSP). A
complete description of the methods of the DSP has
been previously published [34]. Eligible physicians com-
pleted a physician-reported patient record form for the
next 5 consecutive patients with a physician-confirmed
diagnosis of asthma regardless of the reason for the visit.
The physician-reported forms reflected physicians’
knowledge about the health status of patients seeking
routine care. Patients for whom a physician-reported
form was completed were invited to complete a patient-
reported form, with no suggestions from nurses or the
physician.
All diagnostic test and treatment decisions were made
at the discretion of each physician with no tests, treat-
ments, or investigations performed as part of this
prospective, observational, cross-sectional survey. The
survey was performed in full accordance with the US
Health Insurance Portability and Accountability Act
(HIPAA) 1996 [35]. Each patient consented to anonym-
ous, aggregated reporting of research findings as re-
quired by the HIPAA guidelines. The physician-reported
form and the patient-reported form were de-identified
with unique identification numbers assigned to physi-
cians and patients that allowed linkage of a patient-
reported form with the corresponding physician-reported
form.
Subjects
Physicians were identified from lists that were publically
available and contacted by telephone to determine their
eligibility for study participation. Physicians were eligible
to participate in this research if they had completed their
medical training between 1978 and 2008, were person-
ally responsible for treatment decisions and management
of patients with asthma, and saw a minimum of 3 pa-
tients with asthma per week. Survey data were also col-
lected from adult patients with asthma who consulted
with primary care physicians, pulmonologists, or aller-
gists between September and December 2013. Eligibility
criteria for patients included age ≥12 years and a
physician-confirmed diagnosis of asthma with no comor-
bid chronic obstructive pulmonary disease. Patients were
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maintenance therapy and completed all of the questions
on the patient-reported form regarding inhaler device
satisfaction, adherence, asthma control, sleep quality,
and quality of life.
Assessments
The physician-reported form obtained information on
approximately 130 patient and disease variables includ-
ing: demographics; symptoms; exacerbation history;
treatment; smoking status; comorbid health conditions;
physician visits; type of prescribed inhaler device; lung
function test results; and perceptions of patients’ disease
knowledge, engagement, and adherence. Completion of
the physician-reported form required approximately
15 min per patient and physicians were compensated for
their participation.
The patient-reported form included items similar to
those on the physician-reported form as well as assess-
ment of satisfaction with their currently prescribed in-
haler device(s), which could include multiple devices for
maintenance therapy. Patients were not asked to indicate
their satisfaction relating to specific device(s) they were
prescribed (eg, pressurized metered dose inhaler, dry
powder inhaler) based on evidence that patients are
unable to accurately report the names and dosages of
medications, particularly when they take many medica-
tions, are cognitively impaired, or have low health liter-
acy [36, 37]. Rather, they were asked to indicate their
overall satisfaction with 12 attributes of all their current
inhaler device(s), such as consistency of drug delivery,
simplicity of instructions for use, and information about
number of remaining doses. While the questionnaire has
not undergone formal psychometric evaluation, it has
been used for the last 7 years by the Adelphi DSP being
administered to 5006 patients. In addition, expert con-
sultants reviewed and guided the selection and wording
of questions based on their experience, knowledge of the
disease state, and the published literature. The instru-
ment has also been used in previous research to evaluate
relationships between inhaler device satisfaction, patient
adherence, and health outcomes [31]. The 12 attributes
were grouped into 3 domains relating to drug delivery,
device functionality, and device feedback. The decision
to group the 12 attributes into these 3 domains was
guided by expert consensus and disease knowledge. Sat-
isfaction ratings were assessed on a 5-point Likert scale
with a score of 1 indicating not at all satisfied and
a score of 5 indicating very satisfied for each device
feature.
Adherence to current maintenance treatment was
measured with the 8-item Morisky Medication Adher-
ence Scale (MMAS-8) [38]. Patients also completed the
Asthma Control Test (ACT), Jenkins Sleep EvaluationQuestionnaire (JSEQ), and quality of life assessment on
the EuroQol-5D-3L and (EQ-5D-3L). The ACT is a 5-
item questionnaire that assesses recall of symptoms and
daily functioning during the past 4 weeks, with scores
exceeding 19 indicative of well-controlled asthma [39].
The JSEQ is a validated 4-item survey assessing quality
of sleep in the preceding 4 months, with scores ranging
from 0 to 20 and higher scores associated with worse
sleep quality [40]. The EQ-5D-3L is also a validated,
standardized instrument that assesses 5 life dimen-
sions, including mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. Results indicate
1 of 3 levels of severity ranging from no problems to
some or moderate problems, or extreme problems within
each of the 5 dimensions [41]. On average, it took
approximately 20 min for patients to complete the
patient-reported form and the validated patient-reported
outcome (PRO) instruments. Patients received no com-
pensation for completion of the patient-reported form
and the PROs.
Statistical analysis
We calculated descriptive statistics for all variables in-
cluding percent responses for categorical variables and
means with standard deviations for continuous variables.
Partial least squares path modeling was used to quantify
inner model relationships between latent variables [42].
All statistical analyses were performed with Stata/SE ver-
sion 13.1 [43] and R version 3.0 [44].
Partial least squares path modeling is a multivariate
analysis method that examines a system of linear rela-
tionships between multiple sets of variables. It is based
on the assumption that each set of variables is repre-
sented by a latent variable or theoretical concept. Indi-
vidual variables within each set of variables are referred
to as manifest variables because they are a manifestation
of the latent variable or theoretical concept. Seven
latent variables were included in the model (Table 1):
1) patient-reported satisfaction with inhaler device
drug delivery attributes, 2) patient-reported satisfaction
with inhaler device functionality attributes, 3) patient-
reported satisfaction with inhaler device feedback attri-
butes (Table 2), 4) comorbid AR, 5) adherence based on
the MMAS-8, 6) physician-reported smoking history
(ever smoked, total years smoked, and amount smoked
per day), and 7) clinical outcomes (physician-reported
number of asthma exacerbations in preceding 12 months
and PROs on the ACT, JSEQ, and EQ-5D-3L). Exacerba-
tions were defined as a worsening of symptoms that
exceeded normal day-to-day variations.
Direct paths were hypothesized between 1) patient-
reported inhaler satisfaction with drug delivery attributes,
device functionality attributes, and device feedback attri-
butes and adherence, 2) adherence and clinical outcomes,
Table 1 Latent and manifest variables included in the partial
least squares model
Latent Variable Manifest Variable
Drug delivery satisfaction Satisfaction: I get the same amount
of medicine delivered to my lungs
each time.
Satisfaction: I do not need to breathe
in hard to inhale my medicine.
Satisfaction: Low/no irritation in
mouth and throat.
Satisfaction: I do not need to breathe
in at the same time as I press
my inhaler.
Device functionality satisfaction Satisfaction: The instructions are
simple and easy to use.
Satisfaction: It is built to last and
will not break easily.
Satisfaction: No need for me to put
the medicine in the inhaler before
I use it.
Satisfaction: Easy to hold and carry
around with me.
Satisfaction: Can reuse the inhaler
for more than one month.
Device feedback satisfaction Satisfaction: It tells me how many
doses of medicine I have left.
Satisfaction: The inhaler locks when
empty so it cannot be used anymore.
Satisfaction: It tells me when my
dose of medicine has been inhaled
correctly.
Comorbid allergic rhinitis Physician-reported concomitant
allergic rhinitis
Treatment adherence MMAS-8
Smoking history Whether patient ever smoked
(clinician-reported)
Clinician-reported cigarettes smoked
per day
Clinician-reported years smoked
cigarettes for
Clinical outcomes Clinician-reported number of asthma
exacerbations in preceding 12 months
ACT score
JSEQ score
EQ-5D-3L score
ACT, Asthma Control Test; EQ-5D-3L, EuroQol-5D-3L; JSEQ, Jenkins Sleep
Evaluation Questionnaire; MMAS-8; Morisky Medication Adherence Scale
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clinical outcomes, 5) smoking history and clinical out-
comes, 6) smoking history and satisfaction with inhaler
device drug delivery attributes, and 7) satisfaction with
inhaler device drug delivery attributes and clinical out-
comes. Our hypotheses about the relationships among
the latent variables were based on expert consensusand interpretation of results from previous administrations
of the DSP. Of the 3 domains associated with satisfaction,
we hypothesized that only inhaler device drug delivery at-
tributes would have a direct path to clinical outcomes. This
was based on our assumption that satisfactory drug deliv-
ery would have a direct effect on clinical outcomes because
drug delivery is most likely to be associated with symptom
improvements.
Results
A total of 1075 asthma patients were recruited. Physician-
completed forms and patient-completed forms were
obtained for 660 of the 1075 patients, with 493 of these
prescribed maintenance inhaler therapy. Of these, 243 pa-
tients were eligible for this analysis with complete data on
all questions required for the path model (Fig. 1). A total
of 209 physicians completed at least 1 physician-reported
form, including 90 primary care physicians, 89 pulmonolo-
gists, and 30 allergists. Demographic and clinical character-
istics of patients included in the model are summarized
in Table 1, with 20.99 % (n = 51) reported to be current
(3.29 %; n = 8) or prior smokers (17.70 %; n = 43). Almost
half (47.33 %; n = 115) had comorbid AR.
Patient outcomes
Overall, 41 % of patients had poorly controlled asthma
based on the ACT with 45 % reported to have had 1 or
more exacerbation and a mean of 1.1 exacerbations in
the preceding 12 months. The mean JSEQ score was 4.0,
equivalent to patient-reported sleep disruptions at least
1 night per week on average; 29 % of patients had JSEQ
scores of 6 or higher. Overall patient-reported health
status was high based on a mean EQ-5D-3L score of 0.9
(Table 2).
Device satisfaction
Patients reported the highest level of satisfaction for
attributes associated with inhaler device functionality,
with scores ranging from 3.87 to 4.05 for 4 of 5 dimen-
sions. Receiving the same amount of medicine to the
lungs with each use received the highest ranking among
drug delivery attributes and information about the num-
ber of doses remaining was the most highly-rated attri-
bute for device feedback (Table 3). High satisfaction
scores were also evident for the device functionality
attributes of simple, easy-to-use instructions for the de-
vice, no need to put medication in the device prior to
use, device durability, and ease of device portability.
Lower levels of satisfaction were reported for the attri-
butes of being usable for more than 1 month, providing
feedback that the medication dose was correctly inhaled,
and device locking to prevent use of an empty inhaler.
Scores on the MMAS-8 revealed that 24 % (n = 57) of
patients demonstrated high adherence to their medication
Table 2 Demographic and clinical characteristics of patients
(N = 243)
Characteristic
Age, years
• Mean (SD) 40.69 (15.52)
• Range 12.0-78.0
• Median 41.0
• IQR 27.0, 52.0
Gender, n (%)
• Female 132 (54.32)
Ethnicity
• Caucasian 177 (72.84)
Body mass index, mg/kg2
• Mean (SD) 28.15 (6.85)
• Range 15.21-54.71
• Median 26.58
• IQR 23.34, 31.19
Body mass index, mg/kg2, n (%)
• Underweight (<18.5) 4 (1.72)
• Normal (18.5-24.9) 86 (36.91)
• Overweight (25–29.9) 73 (31.33)
• Obese (>30.0) 70 (30.04)
Smoking status, physican-reported, n (%)
• Current smoker 8 (3.29)
• Ex-smoker 43 (17.70)
• Never smoked 192 (79.01)
Physician-reported pack years, n (%)
• High (≥10) 29 (11.93)
• Low (<10) 22 (9.05)
• Never smoked 192 (79.01)
Lung function (FEV1)
• Mean (SD) 73.65 (17.80)
• Range 25.0-138.0
• Median 70.0
• IQR 63.5, 82.0
Frequency of asthma exacerbations in last
12 months
• Mean (SD) 1.08 (1.90)
• Range 0.0-14.0
• Median 0.0
• Range 0.0, 2.0
Frequency of asthma exacerbations in last
12 months, n (%)
• 0 134 (55.14)
• 1 44 (18.11)
• ≥2 65 (26.75)
Table 2 Demographic and clinical characteristics of patients
(N = 243) (Continued)
Deyo Charlson Comorbidity Indexa [58]
• Mean (SD) 0.13 (0.53)
• Range 0-6
• Median 0
• IQR 0, 0
Most common concomitant conditions, n (%)
• Allergic rhinitis 115 (47.33)
• Gastroesophageal reflux disease 42 (18.26)
• Anxiety 36 (15.65)
• Obesity 27 (11.74)
• Cardiovascular diseasec 15 (6.17)
• None 45 (18.52)
Physician managing patient’s asthma, n (%)
• Primary care- only 69 (28.40)
• Specialist-led 174 (71.60)
Morisky Medication Adherence Scale, n (%)
• Low 97 (39.92)
• Medium 89 (36.63)
• High 57 (23.46)
Asthma Control Test
• Mean (SD) 19.91 (3.94)
• Range 6-25
• Median 20
• IQR 18, 23
Asthma Control Test, n (%)
• 5-19 (Not well controlled) 99 (40.74)
• ≥20 (Well controlled) 144 (59.26)
Jenkins Sleep Evaluation Questionnaireb
• Mean (SD) 4.02 (4.53)
• Range 0-20
• Median 3
• IQR 0, 6
Jenkins Sleep Evaluation Questionnaireb, n (%)
• 0 76 (31.28)
• 1-5 97 (39.92)
• 6-10 44 (18.11)
• 11-15 21 (8.64)
• 16-20 5 (2.06)
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Table 2 Demographic and clinical characteristics of patients
(N = 243) (Continued)
EuroQol-5D-3L
• Mean (SD) 0.91 (0.14)
• Range 0.27-1
• Median 1
• IQR 0.84, 1
aConditions as described by Deyo–Charlston index [57] are mapped from as many
as 10 reported ICD-9-CM secondary diagnosis codes. A single summary cumulative
value is represented. A score of 0 represents no comorbidities. Out of the
17 conditions, this research could accommodate 12 including: myocardial
infarction, congestive heart failure, peripheral vascular disease, dementia,
diabetes mellitus, cerebrovascular disease, COPD, connective tissue disease, mild
liver disease, ulcer diagnosis, moderate or severe renal disease, any malignancy
including lymphoma and leukemia, and acquired immunodeficiency syndrome.
Missing data for a specific variable on the physician-reported form or the patient-
reported from resulted in exclusion of the subject from the individual analysis for
that variable but inclusion on all analyses for which data were not missing
bHigher score on the JSEQ indicates greater levels of sleep disturbance
cCardiovascular disease excludes hypertension and hyperlipidaemia. FEV1, forced
expiratory volume in 1 s; IQR, interquartile range; SD, standard deviation
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and 40 % (n = 97) had low adherence.
Path modeling for patient outcomes
Cronbach’s alpha [Cronbach 1951] provides a measure
of consistency for a group of variables. Cronbach’s al-
phas of 0.81 for inhaler device drug delivery satisfaction,
0.83 for inhaler device functionality satisfaction, 0.75 for
inhaler device feedback satisfaction, 1.00 for comorbid
AR, 1.00 for adherence, 0.91 for smoking history, and
0.713 for outcomes indicated unidimensionality of the
manifest variables for each latent variable. Unidimen-
sionality demonstrates that variables are moving in the
same direction, which implies they are manifestations of
the same underlying latent variable. Cross-loadings or
correlations revealed that all manifest variables were as-
sociated with appropriate latent variables in the hypothe-
sized model.
More favorable clinical outcomes were significantly as-
sociated with greater patient satisfaction with drug deliv-
ery (P = 0.002), higher medication adherence (P = 0.049),
a negative history for tobacco use (P < 0.001), and no
comorbid AR (P = 0.005). The R2 for outcomes (the
proportion of variability in outcomes explained by the
model) was 13.3 % and the pseudo goodness of fit (a
measure of the overall prediction performance of the
path model) was 19.5 % (Fig. 2).
Discussion
Our findings confirm multiple factors are predictive of
patients’ degree of asthma control, including satisfaction
with attributes of inhaler devices, adherence, concomi-
tant health conditions, and tobacco use. Notably, drug
delivery attributes of the inhaler device and higheradherence to treatment were significantly associated
with more favorable patient outcomes, including better
asthma control, improved quality of sleep, better overall
health status, and lower frequency of asthma exacerba-
tions. While satisfaction with device functionality and
device feedback were not significantly associated with
clinical outcomes, the ability to properly use the device
and understand device feedback are related to optimal
delivery of medication and likely play a role in device
satisfaction and improved asthma management. In con-
trast, concomitant AR and smoking history were signifi-
cantly associated with poor asthma control.
While the 3 inhaler device satisfaction domains of de-
livery, functionality, and feedback were not significantly
associated with treatment adherence, the relationship
between satisfaction and adherence was in the expected
direction of greater satisfaction resulting in better adher-
ence. Additional research is needed to further refine our
understanding of the relationship between different attri-
butes of inhaler devices and adherence to treatment.
However, the trend for higher rates of adherence among
patients who were more satisfied with their inhaler
device in our research is consistent with results from re-
search examining the association between patient satis-
faction with treatment regimens and adherence across
diverse chronic health conditions [6, 29–32]. A system-
atic review revealed significant associations between
higher treatment satisfaction and better treatment ad-
herence and persistence for patients with glaucoma,
diabetes, osteoporosis, or schizophrenia [29]. Two cross-
sectional surveys of adults receiving medical therapy for
chronic diseases revealed that dissatisfaction with their
medication schedule, side effects, and the burden of
receiving treatment were significant predictors of
intentional nonadherence [30]. Among older patients
with asthma, adjusted multivariate models revealed
that treatment dissatisfaction (characterized by weak
perceptions of the benefits and need for treatment,
and treatment safety concerns) was an independent
predictor of nonadherence [6]. In turn, medication
adherence is predictive of clinical outcomes [45], with
nonadherence to asthma medications associated with
poor control, exacerbations, hospitalizations, and de-
clines in lung function [46].
Attributes that were associated with device satisfaction
in this study included patient perceptions of consistency
in the amount of drug delivery to the lungs, ease of use,
and feedback about the number of remaining doses. As
reported in our results, the correlations revealed that all
manifest variables were associated with the appropriate
latent variables in the hypothesized model. This offers
confirmation that the appropriate domains had been
selected for the 12 device satisfaction attributes. While
beyond the scope of our research, future investigations
Fig. 1 Patient study cohort
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attributes within the 3 domains to include statistical
comparisons of differences between device attributes
and their impact on patient outcomes.
Our analysis suggests that a direct relationship may
exist between inhaler satisfaction and clinical outcomes.
Therefore, clinicians may need to address issues related
to patient satisfaction with inhaler devices in order to
achieve optimal clinical outcomes. Specifically, clinicians’
choice of inhaler device and provision of patient educa-
tion on optimal techniques for device utilization may in-
crease patient satisfaction as well as adherence with
device therapy [47, 48]. Alternative models might also
predict relationships between behaviors, treatment,
therapeutic adherence, and clinical outcomes in patients
affected by asthma. This will be a fruitful area for future
clinical and psychometric research to further clarify
independent and correlated predictors of clinical outcomes,
which has the potential to provide clinicians with informa-
tion to improve the management of their patients with
asthma.
Our findings suggest tobacco use and concomitant AR
are associated with poorer clinical outcomes in patients
with asthma. While the percentage of current smokers
was low in our study at 3.29 %, it is possible that physi-
cians underestimated current smoking rates in their pa-
tients due to patient inaccurately identifying themselves
as never or past smokers. A cross-sectional study of pa-
tients with respiratory disorders revealed low concord-
ance between self-reported tobacco use and objectivemeasures of smoking. Among patients with asthma,
29 % of those who self-identified as nonsmokers or past
smokers had objective measures indicative of current to-
bacco use [49]. These results suggest that patients fre-
quently provide inaccurate information about their
current smoking status to their clinicians. This could be
a possible explanation for our finding that a past history
of tobacco use was associated with less favorable clinical
status because patients classified as past tobacco users
had not actually discontinued smoking.
Furthermore, tobacco use and AR are both modifiable
factors and have the potential to improve asthma control
in patients with appropriately targeted therapy. For ex-
ample, previous research has shown that tobacco use is
associated with decreased efficacy of ICS-containing
maintenance regimens [21, 23, 26]. Therefore, the choice
of medical therapy may need to be tailored to patients
who are current or past smokers. In particular, current
smokers with asthma may require treatment with higher
doses of traditional ICS, extra-fine ICS formulations to
reduce small airway inflammation [50], leukotriene re-
ceptor antagonists, or combination therapy with extra-
fine ICS and long-acting beta-agonists or leukotriene
receptor antagonists [21]. The co-occurrence of AR in
patients with asthma has been shown by other re-
searchers to negatively affect patient outcomes [15, 16],
with 65.7 % of patients with moderate-to-severe persist-
ent AR experiencing inadequate asthma control due to
increased inflammation of the lower airways [16]. Inter-
ventions to promote smoking cessation, tailored therapies
Table 3 Patient-reported satisfaction with categories of inhaler
device attributes
Ratinga
Drug Delivery Satisfaction
I get the same amount of medicine delivered to my
lungs each time
• Mean (SD) 3.79 (0.88)
• Range 1-5
• Median 4
• IQR 3, 4
I do not need to breathe in hard to inhale my medicine
• Mean (SD) 3.58 (1.02)
• Range 1-5
• Median 4
• IQR 3, 4
Low/no irritation in mouth and throat
• Mean (SD) 3.45 (1.07)
• Range 1-5
• Median 3
• IQR 3, 4
I do not need to breathe in at the same time as I press my inhaler
• Mean (SD) 3.42 (1.12)
• Range 1-5
• Median 3
• IQR 3, 4
Device Functionality
The instructions are simple and easy to use
• Mean (SD) 4.05 (0.83)
• Range 1-5
• Median 4
• IQR 4, 5
It is built to last and will not break easily
• Mean (SD) 3.94 (0.83)
• Range 1-5
• Median 4
• IQR 3, 5
No need for me to put the medicine in the inhaler
before I use it
• Mean (SD) 3.97 (0.95)
• Range 1-5
• Median 4
• IQR 3, 5
Easy to hold and carry around with me
• Mean (SD) 3.87 (0.92)
• Range 1-5
• Median 4
• IQR 3, 5
Table 3 Patient-reported satisfaction with categories of inhaler
device attributes (Continued)
Can reuse the inhaler for more than one month
• Mean (SD) 2.89 (1.36)
• Range 1-5
• Median 3
• IQR 2, 4
Device Feedback Satisfaction
It tells me how many doses of medicine I have left
• Mean (SD) 3.72 (1.14)
• Range 1-5
• Median 4
• IQR 3, 5
The inhaler locks when empty so it cannot be used anymore
• Mean (SD) 3.08 (1.32)
• Range 1-5
• Median 3
• IQR 2, 4
It tells me when my dose of medicine has been inhaled
correctly
• Mean (SD) 3.06 (1.27)
• Range 1-5
• Median 3
• IQR 2, 4
a1 = not at all satisfied; 5 = very satisfied. SD, standard deviation. IQR, interquartile
range; SD, standard deviation
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apies to improve the management of AR may improve out-
comes for patients with asthma [16, 51].
In addition to proper selection of medical therapies
for patients with AR and those who are current or past
users of tobacco products, our findings suggest that in-
creased patient satisfaction with inhaler devices pro-
vides clinicians with a modifiable treatment option to
improve clinical outcomes and quality of life for their
patients with asthma. Proper use of inhaler devices and
patient adherence with medical therapies for asthma
are suboptimal, with a wide variety of factors contribut-
ing to improper use of devices, satisfaction with in-
halers, and medication adherence [10, 52, 53]. More
efficient use of inhaler devices, better device technology
to ensure drug delivery, and device design that pro-
motes adherence have the potential to improve control
of asthma [54].
Several limitations should be considered in the evalu-
ation of our findings. We assessed a number of patient
and clinical variables but this was not an exhaustive list
of all factors that might influence clinical outcomes in
patients with asthma. Additional factors associated with
Fig. 2 Partial least squares path modeling analysis examining the relationship between inhaler device satisfaction, medication adherence,
smoking history, allergic rhinitis, and patient outcomes
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lower socioeconomic status, the failure to recognize
symptoms associated with exacerbations, lack of asthma
self-management education [55], poor recognition of
asthma triggers [56], and poor disease knowledge [57].
Future research may include these variables as well as
treatment adherence and satisfaction to identify patients
at risk for poor disease control. The cross-sectional de-
sign of this study prevents any conclusions about causal
relationships between these variables and patients’ clin-
ical outcomes, which could potentially be evaluated in a
longitudinal study.
The proportion of variability in outcomes explained by
the model was 13.3 % and the pseudo goodness of fit
was 19.5 %. Although these values are not particularly
high, it is not unusual to obtain lower values for R2 or
goodness of fit when predicting human behavior. The
demonstration of statistically significant relationships is
of interest and potentially of clinical value.
Furthermore, the DSP was not based on a true random
sample of physicians or patients. While minimal inclu-
sion criteria governed the selection of the participating
physicians, participation might have been influenced by
willingness to complete the survey and practical consid-
erations of location. We were not able to evaluate differ-
ences in our results attributable to physician specialty.
We recognize that the level of knowledge and manage-
ment strategies for asthma might differ between primary
care physicians and pulmonologists and such differences
might affect treatment satisfaction and clinical out-
comes. This presents an opportunity for exploration infuture research. Fully completed physician-reported
forms and patient-reported forms were obtained for 243
of the 493 eligible patients, equivalent to a 49 % response
rate. It is unclear whether this may have introduced a
bias to our results.
While our research design included methods to ensure
that physicians and staff were unaware of patient re-
sponses on the patient-reported forms, it was not pos-
sible to confirm that no information exchange occurred
between physicians and their patients. This has the
potential to undermine the accuracy of estimated
treatment adherence as well as patient responses to
the standardized PRO questionnaires and the assess-
ment of inhaler device satisfaction. Recall bias might
also have affected the responses of both patients and
physicians to the questionnaires, which is a common
limitation of surveys. However, the data for these
analyses were collected at the time of each patient’s
appointment and this is expected to reduce the likeli-
hood of recall bias.
Despite these limitations, our findings provide valu-
able real-world physician- and patient-matched re-
sults suggesting that proper selection of inhalation
devices and patient education combined with im-
proved medication adherence, optimal treatment of
AR and smoking cessation and/or tailoring medical
therapy for current smokers, may lead to more favor-
able clinical outcomes. Addressing one or all of these
areas has potential to decrease patients’ risk of exacerba-
tions and improve asthma control and overall quality of
life.
Price et al. World Allergy Organization Journal  (2015) 8:26 Page 10 of 11Conclusions
Significant predictors of better asthma control, improved
quality of sleep, better overall health status, and lower
frequency of asthma exacerbations were associated with
greater treatment adherence and patient satisfaction
with attributes of their inhaler device, including percep-
tions of consistency in the amount of drug delivery to
the lungs, ease of use, and feedback about the number
of remaining doses. AR and history of tobacco use were
also significantly and negatively associated with disease
control. These findings provide clinicians with strategies
that can be tailored to the individual patient to improve
clinical outcomes. Specifically, choice of inhaler device
and provision of patient education to ensure optimal use
of the device as well as treatment of concomitant AR
and consideration of the patient’s smoking history are
modifiable factors that may optimize asthma control and
improve the quality of life for patients with asthma.
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